Pipeline

Driven by our therapeutic area-agnostic platform

INDICATIONS

CELL  TARGET

RESEARCH

lead  optimization

ind  enabling

phase 1

DERMATOLOGY (rbo-0987)

Age-related Chronic Dermatitis
and others

Pro-Inflammatory Degenerative

phase 1

pulmonary (RBO-0618)

Respiratory Conditions (IPF, COPD, others)

senescent

phase 1

fibrosis (rbo-1597)

Liver, Kidney, Others Undisclosed

Senofibrotic

phase 1

neuro musculo-skeletal

Frailty, Sarcopenia

Senescent-like

phase 1

SCIENTIFIC COLLABORATIONS

Lung Fibrosis

Cory Hogaboam, PhD

Biogerontology

Cellular Senescence Discovery
Judith Campisi, PhD

Muscle Aging and Frailty

Thomas Rando, MD, PhD

Artificial Intelligence in Drug Discovery Chemoinformatics

Francesca Grisoni, PhD

Cory Hogaboam, PhD

Cedars-Sinai Professor of Medicine, Chronic Lung Diseases

Dr. Cory M. Hogaboam, PhD is a Professor of Medicine in the Women’s Guild Lung Institute at Cedars Sinai Medical Center. Dr. Hogaboam is also an Adjunct Professor of Pathology at the University of Michigan Medical School. His research group currently employs genomic, proteomic and bioinformatic approaches to analyze mechanisms contributing to fibrotic and immune system-directed responses in idiopathic pulmonary fibrosis (IPF), lung cancer, sarcoid, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), and asthma utilizing human tissue- and blood-derived cells including fibroblasts, mesenchymal progenitors and various immune cell types that are typically present in abundance in these pulmonary diseases. His group also uses translational approaches through the development of humanized SCID mouse models of IPF, cancer, and asthma. He earned a Bachelor of Science degree in Zoology from the University of Calgary, AB, Canada in 1989. He also holds a Doctorate in Pharmacology (1993) from the same institution. Dr. Hogaboam then engaged in Postdoctoral training in Immunology at McMaster University, Hamilton, ON, Canada from 1993 to 1996. In 1996, Dr. Hogaboam joined the faculty of the Department of Pathology at the University of Michigan Medical School as a Visiting Scholar. He became a faculty member of the Department at the rank of Research Investigator in 1998, Assistant Professor in 2002, Associate Professor in 2004, and full Professor in 2008. Dr. Hogaboam joined the faculty at Cedars Sinai Medical Center in September of 2013. Hogaboam is a member of several professional organizations including the American Association of Immunologists, the American Thoracic Society, and the American Association of Allergy, Asthma and Immunology. He is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight. Dr. Hogaboam has authored or co-authored approximately 281 peer-reviewed manuscripts and 31 book chapters. He has authored or co-authored 11 patents on therapeutic interventions for lung and liver. Dr. Hogaboam has received financial research support from the National Institutes of Health, American Lung Association, Canadian Institutes of Health Research, and several Industry sponsors.

Pipeline

Driven by our therapeutic area-agnostic platform

INDICATIONS

CELL TARGET

RESEARCH

lead optimization

ind enabling

phase 1

DERMATOLOGY (rbo-0987)

Age-related Chronic Dermatitisand others

Pro-Inflammatory Degenerative

phase 1

pulmonary (RBO-0618)

Respiratory Conditions (IPF, COPD, others)

senescent

phase 1

fibrosis (rbo-1597)

Liver, Kidney, Others Undisclosed

Senofibrotic

phase 1

neuro musculo-skeletal

Frailty, Sarcopenia

Senescent-like

phase 1

SCIENTIFIC COLLABORATIONS

Lung Fibrosis

Cory Hogaboam, PhD

Biogerontology

Cellular Senescence Discovery Judith Campisi, PhD

Muscle Aging and Frailty

Thomas Rando, MD, PhD

Artificial Intelligence in Drug Discovery Chemoinformatics

Francesca Grisoni, PhD

Copyright 2022 by Rubedo Life Sciences, Inc.

Ali SIAM

Chief Business Officer

Francesca Grisoni, PhD

Eindhoven University of Technology Assistant Professor, Molecular Machine Learning

Mark Pegram, MD

Stanford University School of Medicine Professor, Medical Oncology

Lidia Schapira, MD

Stanford School of Medicine Professor, Medical Oncology

Jeff Jasper, PhD

Scientific Advisor, Drug discovery & Pharmacology

Paul Insel, MD

University of California San Diego Emeritus Professor of Medicine and Pharmacology

Cory Hogaboam, PhD

Cedars-Sinai Professor of Medicine, Chronic Lung Diseases

Mario E. Lacouture, MD

Memorial Sloan Kettering Cancer Center Dermatologist

Joanna Green, PhD

Ahren Innovation Capital Investment Professional

Robert Gould, PhD

Robert Gould, PhD Khosla Venture Partner

MARK gallop, PhD

Co-Founder, Chairman, Chemistry and Development

julian klein

Co-Founder, Research

alex laslavic, PhD

Chief Technology Officer, Bioinformatics and IT

ALBERTO VITARI, PhD

Senior Director, Discovery Research

OFIR MORENO, PHD

OFIR MORENO, PHD SVP Drug Discovery

mark gallop,phd

Co-Founder, Chairman Chemistry and Development

Judith Campisi, PhD

Buck Institute for Research & Aging Professor, Biogerontology

Marco Quarta, PhD

Co-Founder and CEO

Marco Quarta, PhD

Co-Founder and CEO

CELL  TARGET

lead  optimization

ind  enabling

Age-related Chronic Dermatitis
and others

Cellular Senescence Discovery
Judith Campisi, PhD